Company intelligence / Profile preview

Exact Sciences Laboratories

Madison, Wisconsin, United States

Ownership: Private
Employees: ~6500
Development stage: Other

Overview

Exact Sciences has several marketed products for the early detection and management of multiple cancers (notably colorectal and breast), including FDA-approved Cologuard and the Oncotype DX portfolio; clinical studies, such as the BLUE-C study, demonstrate high sensitivity for early cancer detection, and the newly launched Cancerguard test aims to broaden early multi-cancer detection using blood-based biomarkers.[1][2][3][10][14]

Therapeutic areas: Oncology
Modalities: Diagnostic testGenomic assayBiologicDevice
Industry: Molecular Diagnostics

Partnerships

Mayo ClinicEpic SciencesNHS (England, for test access)Various hospital and health system partners

Beyond the preview

Go deeper on Exact Sciences Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exact Sciences Laboratories.

Explore the full profile